BlueArc Biosciences is proud to announce that we've been selected as a Phase 3 winner in the LymeX Diagnostics Prize. With an estimated 476,000 cases in America annually, the U.S. has an urgent need for new Lyme Disease diagnostics. The BlueArc test is designed to detect Borrelia infection from the first symptoms. The funding from LymeX is helping us accelerate the development of our diagnostic towards clinical trials. The LymeX Diagnostics Prize is made possible through a pledge of more than $10 million from the @Steven & Alexandra Cohen Foundation with the purpose of advancing scientific, technical, and clinical innovation to create better diagnostic for #Lyme disease. Learn more about our Lyme diagnostic and Phase 3 support: https://lnkd.in/gdUAtWma
关于我们
- 网站
-
https://www.bluearcbio.com
BlueArc Biosciences的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- La Jolla，CA
- 类型
- 私人持股
地点
-
主要
获取路线
US，CA，La Jolla，92037